Singapore markets open in 5 hours 43 minutes

Candel Therapeutics, Inc. (CADL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
12.67+1.97 (+18.38%)
As of 03:17PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close10.70
Open10.83
Bid12.59 x 200
Ask12.74 x 200
Day's range10.73 - 12.97
52-week range0.66 - 12.97
Volume1,153,827
Avg. volume5,617,901
Market cap371.836M
Beta (5Y monthly)-0.93
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

    Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancerPhase 2 topline overall survival data for CAN-2409 in non-small cell lung cancer (NSCLC), to be presented at ASCO on June 3, 2024On track for topline disease-free survival data from CAN-2409 phase 3 clinical trial in localized intermediate/high risk prostate cancer, expected in Q4 2024 NEEDHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Can

  • GlobeNewswire

    Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

    NEEDHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that two abstracts were accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 to June 4, 2024, in Chicago, IL. The first presentation will feature data from the ongoing

  • GlobeNewswire

    Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer

    NEEDHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer. “We recently reported dat